Longeveron says new Phase 2a analysis of laromestrocel in mild Alzheimer’s accepted for AAIC 2026 poster presentation

Longeveron

Longeveron

LGVN

0.00
  • Longeveron flagged an additional analysis from its Phase 2a CLEAR MIND study of laromestrocel in mild Alzheimer’s disease.
  • Results were already published in Nature Medicine in March 2025, supporting potential benefit and backing continued clinical development.
  • The new analysis will be presented at the 2026 Alzheimer’s Association International Conference in London on July 13.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606180920PRIMZONEFULLFEED9748983) on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.